Moneycontrol
Get App
Last Updated : Oct 10, 2019 11:05 AM IST | Source: Moneycontrol.com

Morgan Stanley bullish on these 2 pharma stocks which could give 32-47% return

Morgan Stanley also has overweight rating on Lupin with a target price at Rs 1,003, implying 47 percent potential upside from current levels as it believes the share price will rise in absolute terms over the next 30 days.

Moneycontrol News @moneycontrolcom
Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

The healthcare sector has been under pressure for many quarters now amid earnings weakness, US pricing concerns and USFDA worries. The Nifty Pharma index fell more than 18 percent against the 4 percent rally in the Nifty50.

Even in the last 30 months, the Healthcare index plunged 28 percent whereas the Nifty50 shot up 20 percent. During the same period, Lupin corrected 46 percent, Sun Pharma 40 percent and Cipla 25 percent.

Hence, the valuations turned attractive and, with expected improvement in earnings, there could be rerating in coming days, brokerages feel.

Close

Global brokerage house Morgan Stanley turned bullish on Sun Pharma and Lupin as it has overweight rating on both stocks with a target price at Rs 505 and Rs 1,003 per share, implying 32 percent and 47 percent potential upside from current levels respectively.

In case of Sun Pharma, the research firm believes the share price will rise in absolute terms over the next 30 days as the short-term valuation is much more compelling after the recent fall.

"The stock is trading at 20-25 percent discount to its historical valuation and we believe that the stock can rerate, driven by an earnings recovery," Morgan Stanley said, adding specialty ramp-up should bring incremental upside.

Lupin, as well as Sun Pharma, corrected 67 percent each from their all-time highs touched in October and August 2015 respectively.

Morgan Stanley also has overweight rating on Lupin with a target price at Rs 1,003, implying 47 percent potential upside from current levels as it believes the share price will rise in absolute terms over the next 30 days.

The stock is down 53 percent over the last 30 months against sensex up 27 percent in the same time.

"We expect steady earnings growth (55 percent EPS F20-21e CAGR) over the next two years and product pipeline includes a lucrative opportunity," the brokerage reasoned.

In case of Cipla, "valuations seem attractive at current levels and we believe the share price will rise in absolute terms over the next 30 days," said Morgan Stanley which has equalweight rating on the stock with a target price at Rs 578 per share, implying 36 percent potential upside from current levels.

The brokerage expects Cipla's business to normalise in the medium term.

Disclaimer: The above report is compiled from information available on public platforms. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Oct 10, 2019 11:05 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant